Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.83 USD | +1.79% | +0.56% | +2.85% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
117.3 USD | -4.39% | -6.15% | 44.96B | ||
10.83 USD | +1.79% | +0.56% | 1.12B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.85% | 1.12B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics